The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin.
 
Marianna Koczywas
Speakers' Bureau - AstraZeneca; Celgene
 
Paul Henry Frankel
Honoraria - Geron; Transenterix
Other Relationship - FlexSim; FlexSim
 
Jonathan W. Riess
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Heron; Loxo; Medtronic; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Anthony B. El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche/Genentech
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca; Merck
 
Liza C Villaruz
Consulting or Advisory Role - Achilles Therapeutics
Research Funding - AstraZeneca (Inst); Celgene (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Rain Therapeutics (Inst)
 
Stephen Leong
Stock and Other Ownership Interests - Antares Pharmaceuticals; Spectrum Pharmaceuticals
Honoraria - Lilly
Research Funding - Bristol-Myers Squibb (Inst); Deciphera (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Christopher Ruel
No Relationships to Disclose
 
Timothy W. Synold
No Relationships to Disclose
 
Timothy O'Connor
No Relationships to Disclose
 
Edward M. Newman
No Relationships to Disclose